Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies

American Journal of Cardiology

Volumn 96, Issue 11, 2005, Pages 1530-1536

  Carr, Albert A ^a   Kowey, Peter R ^b   Devereux, Richard B ^c   Brenner, Barry M ^d   Dahlöf, Björn ^e   Ibsen, Hans ^f   Lindholm, Lars H ^g   Lyle, Paulette A ^h   Snapinn, Steven M ^h   Zhang, Zhongxin ^h   Edelman, Jonathan M ^h   Shahinfar, Shahnaz ^h  

^a Circulatory Disease Center   (United States)

^b Main Line Health Heart Center   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^g UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ATENOLOL; CREATININE; LOSARTAN; PLACEBO;

ADULT; AGED; ALCOHOL CONSUMPTION; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STATISTICAL SIGNIFICANCE;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATENOLOL; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 28044445114     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.07.061     Document Type: Article

References (29)

1. B.M. Brenner, M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, H.H. Parving, G. Remuzzi, S.M. Snapinn, Z. Zhang, S. Shahinfar Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
2. B. Dahlöf, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristiansson, O. Lederballe-Pedersen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol Lancet 359 2002 995 1003
3. L.H. Lindholm, H. Ibsen, B. Dahlöf, R.B. Devereux, G. Beevers, U. de Faire, F. Fyhrquist, S. Julius, S.E. Kjeldsen, K. Kristiansson Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol Lancet 359 2002 1004 1010
4. R.B. Devereux, M.J. Roman, M. Paranicas, M.J. O'Grady, E.T. Lee, T.K. Welty, R.R. Fabsitz, D. Robbins, E.R. Rhoades, B.V. Howard Impact of diabetes on cardiac structure and function the Strong Heart Study Circulation 101 2000 2271 2276
5. C. Iribarren, A.J. Karter, A.S. Go, A. Ferrara, J.Y. Liu, S. Sidney, J.V. Selby Glycemic control and heart failure among adult patients with diabetes Circulation 103 2001 2668 2673
6. R.W. Brownsey, A.N. Boone, M.F. Allard Actions of insulin on the mammalian heart metabolism, pathology and biochemical mechanisms Cardiovasc Res 34 1997 3 24
7. D.L. Eckberg, S.W. Harkins, J.M. Fritsch, G.E. Musgrave, D.F. Gardner Baroreflex control of plasma norepinephrine and heart period in healthy subjects and diabetic patients J Clin Invest 78 1986 366 374
8. R.L. Hopfner, V. Gopalakrishnan Endothelin emerging role in diabetic vascular complications Diabetologia 42 1999 1383 1394
9. J. Nilsson, S. Jovinge, A. Niemann, R. Reneland, H. Lithell Relation between plasma tumor necrosis factor-α and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus Arterioscler Thromb Vasc Biol 18 1998 1199 1202
10. D. de Zeeuw, G. Remuzzi, H.H. Parving, W.F. Keane, Z. Zhang, S. Shahinfar, S. Snapinn, M.E. Cooper, W.E. Mitch, B.M. Brenner Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy lessons from RENAAL Kidney Int 65 2004 2309 2320
11. N.K. Hollenberg ACE inhibition, angiotensin II receptor blockade and diabetic nephropathy C.E. Mogensen The Kidney and Hypertension in Diabetes Mellitus 2000 Kluwer Academic Publishers Boston 417 422
12. R.B. Devereux, K. Wachtell, E. Gerdts, K. Boman, M.S. Nieminen, V. Papademetriou, J. Rokkedal, K. Harris, P. Aurup, B. Dahlöf Prognostic significance of left ventricular mass change during treatment of hypertension JAMA 292 2004 2350 2356
13. P.M. Okin, R.B. Devereux, S. Jern, S.E. Kjeldsen, S. Julius, M.S. Nieminen, S. Snapinn, K.E. Harris, P. Aurup, J.M. Edelman, H. Wedel, L.H. Lindholm, B. Dahlöf Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events JAMA 292 2004 2343 2349
14. R.B. Devereux, B. Dahlöf, E. Gerdts, K. Boman, M.S. Nieminen, V. Papademetriou, J. Rokkedal, K.E. Harris, J.M. Edelman, K. Wachtell Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial Circulation 110 2004 1456 1462
15. T.J. Wang, M.G. Larson, D. Levy, R.S. Vasan, E.P. Leip, P.A. Wolf, R.B. D'Agostino, J.M. Murabito, W.B. Kannel, E.J. Benjamin Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality the Framingham Heart Study Circulation 107 2003 2920 2925
16. J.S. Shinbane, M.A. Wood, D.N. Jensen, K.A. Ellenbogen, A.P. Fitzpatrick, M.M. Scheinman Tachycardia-induced cardiomyopathy a review of animal models and clinical studies J Am Coll Cardiol 29 1997 709 715
17. M. Pozzoli, G. Cioffi, E. Traversi, G.D. Pinna, F. Cobelli, L. Tavazzi Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure a prospective study in 344 patients with baseline sinus rhythm J Am Coll Cardiol 32 1998 197 204
18. K. Wachtell, M. Lehto, E. Gerdts, M.H. Olsen, B. Hornestam, B. Dahlöf, H. Ibsen, S. Julius, S.E. Kjeldsen, L.H. Lindholm, M.S. Nieminen, R.B. Devereux Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol the Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study J Am Coll Cardiol 45 2005 712 719
19. B.M. Massie What is the meaning of LIFE? Implications of the Losartan Intervention for Endpoint reduction in hypertension trial for heart failure physicians J Card Fail 8 2002 197 201
20. G. Corrao, L. Rubbiati, V. Bagnardi, A. Zambon, K. Poikolainen Alcohol and coronary heart disease a meta-analysis Addiction 95 2000 1505 1523
21. K. Berger, U.A. Ajani, C.S. Kase, J.M. Gaziano, J.E. Buring, R.J. Glynn, C.H. Hennekens Light-to-moderate alcohol consumption and risk of stroke among U.S. male physicians N Engl J Med 341 1999 1557 1564
22. F. Turnbull Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events results of prospectively-designed overviews of randomised trials Lancet 362 2003 1527 1535
23. R.O. Estacio, B.W. Jeffers, W.R. Hiatt, S.L. Biggerstaff, N. Gifford, R.W. Schrier The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension N Engl J Med 338 1998 645 652
24. UK Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 39 BMJ 317 1998 713 720
25. J.M. Arnold, S. Yusuf, J. Young, J. Mathew, D. Johnstone, A. Avezum, E. Lonn, J. Pogue, J. Bosch Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study Circulation 107 2003 1284 1290
26. L. Vaur, P. Gueret, M. Lievre, S. Chabaud, P. Passa Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study Diabetes Care 26 2003 855 860
27. T. Berl, L.G. Hunsicker, J.B. Lewis, M.A. Pfeffer, J.G. Porush, J.L. Rouleau, P.L. Drury, E. Esmatjes, D. Hricik, C.R. Parikh Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy Ann Intern Med 138 2003 542 549
28. S. Yusuf, M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J. McMurray, E.L. Michelson, B. Olofsson, J. Ostergren Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction the CHARM-Preserved Trial Lancet 362 2003 777 781
29. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997